Drug Profile
Recombinant coagulation factor X - VarmX
Alternative Names: Factor Xa inhibitor reversal agent - VarmX; Modified blood coagulation factor X - VarmX; PseudoXa; VMX-C001Latest Information Update: 24 Apr 2024
Price :
$50
*
At a glance
- Originator VarmX
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haemorrhage
Most Recent Events
- 21 Feb 2024 VarmX initiates a phase I trial for Haemorrhage in (In volunteers) in Netherlands (IV) (NCT06372483)
- 21 Feb 2024 VarmX initiates a phase I trial for Haemorrhage in (In volunteers, Combination therapy) in Netherlands (IV) (NCT06372483)
- 25 May 2023 VarmX intends to file investigational new drug (IND) approval for its lead compound VMX-C001